17 September 2021: Original Paper
Immunological Results of Long-Term Use of Mammalian Target of Rapamycin (mTOR) Inhibitors and Its Effects on Renal Graft Functions
Mehmet Tanrısev 1ABCDEF* , Tülay Ayna Kılıçaslan 2CD , Hülya Çolak 1BFG , Sibel Ersan 1BD , Banu Yılmaz 1BFG , Alper Alp 3B , Cem Tuğmen 4BC , Bahar Engin Sevgili 5EDOI: 10.12659/AOT.932434
Ann Transplant 2021; 26:e932434
Table 1 Comparing demographic and comorbidity variables between groups.
| Variables | mTOR group (n=37) mean±SD | CNI group (n=52) mean±SD | p |
|---|---|---|---|
| Age (year) | 45.2±12.5 | 46.4±12.1 | 0.500 |
| Transplant year | 11.2±4.5 | 9.1±3.9 | |
| Transplant number | 1.03±0.1 | 1.02±0.1 | 0.800 |
| Mismatch | 3.27±0.6 | 3.56±0.6 | |
| Sex (F/M) | 19/18 (51.4/48.6) | 21/31 (40.6/59.4) | 0.300 |
| Presence of DM | 8 (21.6) | 2 (3.8) | |
| Presence of HT | 17 (45.9) | 31 (59.6) | 0.200 |
| Presence of CVD | 2 (5.4) | 1 (1.9) | 0.568 |
| Post-transplant BKVN | 4 (10) | 0 (0) | |
| Post-transplant AR | 4 (10.8) | 7 (13.5) | 0.700 |
| Post-transplant malignancy | 3 (8.1) | 1 (1.9) | 0.300 |
| Delayed graft function | 4 (10.8) | 10 (19.2) | 0.282 |
| Cadaveric donor | 15 (40.5) | 22 (42.3) | 0.867 |
| Live donor | 22 (59.5) | 30 (57.7) | 0.867 |
| Induction therapy | 29 (78.4) | 42 (80.8) | 0.781 |
| Used ATG | 8 (21.6) | 21 (40.4) | 0.236 |
| Used IL-2 antagonist | 21 (56.8) | 21 (40.4) | 0.693 |
| Independent t test was used for comparing age parameter. Pearson’s or Fisher’s exact chi-square tests were used for categorical data. P | |||